Status:
COMPLETED
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
Lead Sponsor:
Solvay Pharmaceuticals
Collaborating Sponsors:
H. Lundbeck A/S
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia and Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
Eligibility Criteria
Inclusion
- Males or females, 18-65 years, meeting DSM-IV TR diagnosis of Schizophrenia or Schizoaffective Disorder for whom a switch is indicated
Exclusion
- Acutely psychotic or with a current Axis I primary psychiatric diagnosis other than schizophrenia or schizoaffective disorder based on DSM-IV TR criteria
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00347425
Start Date
December 1 2006
End Date
February 1 2008
Last Update
May 21 2008
Active Locations (122)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 148
Birmingham, Alabama, United States
2
Site 194
Little Rock, Arkansas, United States
3
Site 178
Anaheim, California, United States
4
Site 167
Cerritos, California, United States